 SHANGHAI and HONG KONG, May 5, 2021 PRNewswire -- Antengene Corporation Limited Antengene, SEHK: 6996.HK, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class andor best-in-class therapeutics in hematology and oncology, today announced that the Chinese Society of Clinical Oncology CSCO, the most prominent organization in oncology in China, added multiple selinexor regimens to its 2021 Diagnosis and Treatment Guidelines CSCO Guidelines for treatment of multiple myeloma and lymphoma. Three selinexor regimens recommended by the Guideline for the Diagnosis and Treatment of myeloma include: i selinexor plus dexamethasone; and ii selinexor plus dexamethasone plus bortezomib; and iii selinexor plus dexamethasone plus pomalidomide for the treatment of relapsed myeloma. 